Aliskiren

Drug Profile

Aliskiren

Alternative Names: Aliskiren fumarate; Aliskiren hemi-fumarate; CGP 60536B; Enviage; Rasilez; Rasilles; Riprazo; SPP 100; SPP 100B; Sprimeo; Tekturna

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Ohio State University
  • Class Amides; Antihypertensives; Fumarates; Small molecules
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension
  • Phase III Chronic heart failure
  • Discontinued Acute heart failure; Atherosclerosis; Diabetic macular oedema; Diabetic nephropathies; Kidney disorders; Myocardial infarction

Most Recent Events

  • 12 Nov 2016 Interim efficacy data from a phase III ASTRONAUT trial in Acute heart failure (Adjunctive treatment) presented at the 89th Annual Scientific Sessions of the American Heart Association (AHA-2016)
  • 06 Jul 2016 Novartis has patent protection for aliskiren in USA and in the European Union
  • 06 Jul 2016 Novartis has patents pending for aliskiren in USA and in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top